Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic kidney disease stage IV not requiring dialysis;~* expected to initiate dialysis within 18 months;~* 15\<=Glomerular Filtration Rate (GFR)\<=29.~Exclusion Criteria:~* failing renal allograft in place;~* acute or chronic bleeding within 8 weeks prior to screening;~* transfusion of red blood cells within 8 weeks prior to screening;~* poorly controlled hypertension;~* immunosuppressive therapy in the 12 weeks prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- methoxy polyethylene glycol-epoetin beta (Type: EXPERIMENTAL): 120-360 micrograms methoxy polyethylene glycol-epoetin beta subcutaneous (sc) monthly starting dose, for a minimum of 5 months to a maximum of 18 months.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL.
- Epoetin alfa (Type: ACTIVE_COMPARATOR): Patients randomized to the reference arm continued to receive their standard of care dose and regimen of epoetin alfa subcutaneous once per week for a minimum of 5 months to a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL.
- Darbepoetin alfa (Type: ACTIVE_COMPARATOR): Patients randomized to the reference arm continued to receive their standard of care dose and regimen of darbepoetin subcutaneous once every two weeks for a minimum of 5 months and a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).